$BIOS News

Last published 3y ago

3y agoBIOSAvertix and BIOS Acquisition Corporation Mutually Agree to Terminate Proposed Business CombinationGlobeNewswireEATONTOWN, N.J. and NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Avertix Medical, Inc. ("Avertix" or the "Company"), formerly known as Angel Medical Systems, Inc., a company focused on improving long-term management and
3y agoBIOS BIOSU BIOSWBioPlus Acquisition Corp. Announces Termination of Business Combination Agreement with Avertix Medical, Inc. and its Intention to LiquidateGlobeNewswireNew York, NY, Oct. 04, 2023 (GLOBE NEWSWIRE) -- BioPlus Acquisition Corp. ("BIOS" or the "Company") (NASDAQ:BIOS) announced today that (i) BIOS, Avertix Medical, Inc. and certain other parties have mutually agreed to
3y agoBIOSCarbonhand is available for Veterans in the USPR NewswireBioservo signs a Sales Agent agreement with Trivet Medical LLC for sales of Carbonhand to Hospitals, Clinics, and Medical Centers within the Veterans Health Administration and Department of Defense in the US. With the
3y agoBIOSHeart & Rhythm Institute of Trinity and Avertix Announce Partnership to Improve Cardiac Care and Patient MonitoringGlobeNewswireThe Avertix Guardian™ System, the first and only FDA approved implantable heart attack warning system, now available at the Heart & Rhythm Institute of Trinity, extending their commitment to redefining cardiac
3y agoBIOSCarbonhand available in the US through Veterans Healthcare Supply SolutionsPR NewswireBioservo signs a wholesale distributor agreement with Veterans Healthcare Supply Solutions for sales of Carbonhand in the US. The initial intent of the agreement is to make Carbonhand available for Veterans
3y agoBIOSRenown Cardiologist and Professor Ian T. Meredith, MD to Join Avertix Medical's Board of DirectorsGlobeNewswireRecently served as Boston Scientific Executive Vice President and Global Chief Medical Officer Professor Meredith brings to Avertix over 35 years of cardiology experience and commitment to advancing cardiac care
3y agoBIOSAvertix's Guardian™ System, First and Only FDA-Approved Implantable Heart Attack Detection and Warning System, Now Available at AdventHealth OrlandoGlobeNewswireEATONTOWN, N.J. and ORLANDO, Fla., June 13, 2023 (GLOBE NEWSWIRE) -- Avertix Medical, Inc. ("Avertix" or the "Company"), formerly known as Angel Medical Systems, Inc., a company focused on improving long-term
3y agoBIOSAvertix, Maker of First and Only FDA-Approved Implantable Heart Attack Warning System, to Become Publicly Traded via Merger with BIOS Acquisition CorporationGlobeNewswire- Transaction values Avertix at an enterprise value of $195 million- Avertix developed the Guardian™ System, the first and only FDA-approved solution designed to detect and warn patients of cardiac events,
3y agoADES BIOS LAZY LOGI+7Purple Innovation Announces Cooperative Framework with Coliseum CapitalBusiness WireCompany to Welcome New Directors to Board Adam Gray to Serve as Board Chair Gary DiCamillo to Continue to Serve as Lead Independent Director Company Will Redeem Cumulative Voting Proportional Representation
3y agoBIOS LAZY LOGI MODV+7Coliseum Nominates Slate of Highly Qualified and Engaged Director Candidates for Election at Purple Innovation 2023 Annual MeetingBusiness WireWill Support Re-Election of CEO Rob DeMartini to Board No Longer Pursuing September 2022 Take Private Proposal Shareholders Deserve Nimbler, More Engaged Board with Heightened Sense of Urgency and Bias for Action to
4y agoMODV OPCH BIOSRiverbed|Aternity Announces Appointment of New Board of DirectorsBusiness WireNew Board Brings Significant and Diverse Experience to Support Company's Growth and Success Riverbed|Aternity (the "Company") today announced that, as part of its recapitalization, which was finalized today, the following seven directors have been ap
4y agoBIOSBioPlus Acquisition Corp. Announces Pricing of Upsized $200,000,000 Initial Public OfferingGlobeNewswireNew York, NY, Dec. 02, 2021 (GLOBE NEWSWIRE) -- BioPlus Acquisition Corp. (the "Company") announced today that it priced its upsized initial public offering of 20,000,000 units at $10.00 per unit. The units will be listed on the Nasdaq Global Market ("
6y agoBIOSOption Care Health to Participate in the 38th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireBANNOCKBURN, Ill., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Option Care Health Inc. (NASDAQ: BIOS), the nation’s largest independent provider of home and alternate site infusion therapy services, will...
6y agoBIOSOption Care Health to Participate in the Bank of America Merrill Lynch 2019 Leveraged Finance ConferenceGlobeNewswireBANNOCKBURN, Ill., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Option Care Health Inc. (NASDAQ: BIOS), the nation’s largest independent provider of home and alternate treatment site infusion therapy services,...
6y agoBIOSOption Care Health Selected by Highmark as Preferred Provider of Hemophilia TreatmentGlobeNewswireBANNOCKBURN, Ill., Nov. 19, 2019 (GLOBE NEWSWIRE) -- Option Care Health, Inc., the nation’s largest independent provider of home and alternate treatment site infusion therapy services, has been...
7y agoBIOSOption Care Health, Inc (BIOS) CEO John Rademacher on Q3 2019 Results - Earnings Call TranscriptEarnings Call Transcripts
7y agoBIOSOption Care Health Announces Third Quarter ResultsGlobeNewswireBANNOCKBURN, Ill., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (Nasdaq: BIOS), the nation’s largest independent provider of home and alternate site infusion services, today announced...
7y agoBIOSOption Care Health to Announce Third Quarter 2019 Financial Results and Host Conference CallGlobeNewswireBANNOCKBURN, Ill., Oct. 16, 2019 (GLOBE NEWSWIRE) -- Option Care Health Inc. (NASDAQ: BIOS), the nation’s largest independent national provider of home and alternate site infusion services, today...
7y agoBIOSOption Care Health to Participate in the Morgan Stanley 17th Annual Global Healthcare ConferenceBusiness WireBANNOCKBURN, Ill.--(BUSINESS WIRE)--Option Care Health Inc. (NASDAQ: BIOS), the nation’s largest independent national provider of home and alternate site infusion services, today announced that John Rademacher, Chief Executive Officer, will participate in a fireside chat on September 10 at the Morgan Stanley Global Healthcare Conference, scheduled to start at 10:00 a.m. EDT. A live audio webcast a ...
7y agoBIOSOption Care Health Receives Anticipated Nasdaq NoticeBusiness WireBANNOCKBURN, Ill.--(BUSINESS WIRE)--Option Care Health, Inc. (Nasdaq: BIOS) announced today that on August 7, 2019, it received a letter from the Nasdaq Staff informing it that, since the merger between Option Care Enterprises, Inc. and BioScrip, Inc. constituted a change of control for purposes of the Nasdaq Listing Rules, Option Care was required to meet all applicable criteria for initial listi ...
7y agoBIOSBioScrip, Inc. (BIOS) CEO Dan Greenleaf on Q4 2018 Results, and BioScrip and Option Care Merger Transaction (Transcript)Earnings Call Transcripts
8y agoBIOSBioScrip, Inc. (BIOS) CEO Daniel Greenleaf on Q3 2018 Results - Earnings Call TranscriptEarnings Call Transcripts
8y agoBIOSBioScrip, Inc. (BIOS) CEO Dan Greenleaf on Q2 2018 Results - Earnings Call TranscriptEarnings Call Transcripts
8y agoBIOSBioScrip Provides Update on Annual Form 10-K Filing StatusBusiness WireDENVER--(BUSINESS WIRE)--BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions, today announced that it will be filing a Form 12b-25 with the U.S. Securities and Exchange Commission to automatically extend the date for filing its Annual Report on Form 10-K for the year ended December 31, 2017 by 15 days ...
8y agoBIOSBioScrip, Inc's (BIOS) CEO Daniel Greenleaf on Q4 2017 Results - Earnings Call TranscriptEarnings Call Transcripts
8y agoBIOSBioScrip Reports Fourth Quarter and Full Year 2017 Financial ResultsBusiness WireDENVER--(BUSINESS WIRE)--BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions, today announced its preliminary 2017 financial results and provided financial guidance for 2018, subject to the completion of the Company’s accounting review described below.
8y agoBIOSBioScrip Schedules Release of Fourth Quarter and Full Year 2017 Financial Results and Conference CallBusiness WireDENVER--(BUSINESS WIRE)--BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions, today announced that the Company will issue its financial results press release for the fourth quarter and full year ended December 31, 2017 on Thursday, March 8, 2018 before the opening of the U.S. financial markets.
8y agoBIOSBioScrip Announces U.S. Congress Passage of Medicare Home Infusion Transition Benefit, Effective 2019Business WireDENVER--(BUSINESS WIRE)--BioScrip, Inc. (NASDAQ:BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions, today announced that the U.S. Congress today passed the Medicare Home Infusion Therapy Access Act of 2017 (H.R. 3163/S. 1738) as part of the Continuing Resolution. The legislation provides for a transitional benefit payment, ...
9y agoBIOSBioScrip's (BIOS) CEO Dan Greenleaf on Q1 2017 Results - Earnings Call TranscriptEarnings Call Transcripts
9y agoBIOSBioScrip, Inc. Joins Coalition to Advocate for Vulnerable Medicare Patients Losing Access to Home Infusion CareBusiness WireDENVER--(BUSINESS WIRE)--BioScrip, Inc. (NASDAQ:BIOS), a leading national provider of infusion and home care management solutions, announced today it has joined a newly established coalition, Keep My Infusion Care at Home, which spans several leading industry constituents working diligently to persuade the U.S. Congress to fix a new law that has caused critically ill, vulnerable Medicare patients ...
10y agoBIOSBioScrip (BIOS) Q3 2016 Results - Earnings Call TranscriptEarnings Call Transcripts
10y agoBIOSBioScrip (BIOS) Q1 2016 Results - Earnings Call WebcastEarnings Call Transcripts
10y agoBIOSBioScrip (BIOS) Richard M. Smith on Q4 2015 Results - Earnings Call TranscriptEarnings Call Transcripts
11y agoBIOSBioScrip Reports Third Quarter 2015 Financial ResultsBusiness WireELMSFORD, N.Y.--(BUSINESS WIRE)--BioScrip, Inc. (NASDAQ:BIOS) (“the Company”) today announced 2015 third quarter financial results.
11y agoBIOSScott+Scott, Attorneys at Law, LLP Announces Investigation of BioScrip, Inc.Business WireNEW YORK--(BUSINESS WIRE)--Scott+Scott, Attorneys at Law, LLP (“Scott+Scott”), a national shareholder and consumer rights litigation firm, announces the commencement of an investigation into BioScrip, Inc. (NASDAQ:BIOS) (“BioScrip”) to determine whether the BioScrip’s Officers and Directors have breached their fiduciary duties owed to BioScrip and its shareholders. If you are a BioScrip shareholde ...
11y agoBIOSLaw Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of BioScrip, Inc. StockholdersBusiness WireNEW YORK--(BUSINESS WIRE)--Kirby McInerney LLP is investigating potential claims against the Board of Directors of BioScrip, Inc. (“BioScrip” or the “Company”) (NASDAQ:BIOS) concerning the Company’s alleged participation in a kickback scheme.
11y agoBIOSThe Shuman Law Firm Investigates BioScrip, Inc.Business WireBOULDER, Colo.--(BUSINESS WIRE)--The Shuman Law Firm announces that it is investigating potential claims against certain officers and directors of BioScrip, Inc. (“BioScrip” or the “Company”) (Nasdaq: BIOS). BioScrip is a New York-based company that provides home infusion and other home care services, and pharmacy benefit management services in the United States.
11y agoBIOSThe Shuman Law Firm Investigates BioScrip, Inc.Business WireBOULDER, Colo.--(BUSINESS WIRE)--The Shuman Law Firm announces that it is investigating potential claims against certain officers and directors of BioScrip, Inc. (“BioScrip” or the “Company”) (Nasdaq: BIOS). BioScrip is a New York-based company that provides home infusion and other home care services, and pharmacy benefit management services in the United States.
13y agoBIOSBioScrip to Present at 31ST Annual J.P. Morgan Healthcare ConferenceBusiness WireELMSFORD, N.Y.--(BUSINESS WIRE)--BioScrip, Inc. (NASDAQ: BIOS) today announced that the Company will present at the 31st Annual J.P. Morgan Healthcare Conference to be held January 7-10, 2013 at the Westin St. Francis in San Francisco, CA.
13y agoBIOS DVABioScrip Enters into Agreement to Acquire HomeChoice Partners, Inc.Business WireELMSFORD, N.Y.--(BUSINESS WIRE)--BioScrip, Inc. (NASDAQ: BIOS) today announced that it has entered into a definitive agreement to acquire HomeChoice Partners, Inc. (“HomeChoice”), a leading provider of alternate-site infusion pharmacy services, for $70.0 million in cash. HomeChoice is a majority-owned subsidiary of DaVita HealthCare Partners Inc. (NYSE: DVA). The purchase price is subject to adjus ...
13y agoBIOSBioScrip to Present at Oppenheimer 23rd Annual Healthcare ConferenceBusiness WireELMSFORD, N.Y.--(BUSINESS WIRE)--BioScrip, Inc. (NASDAQ: BIOS) today announced that the Company will present at the Oppenheimer 23rd Annual Healthcare Conference to be held December 12-13, 2012 at the Waldorf=Astoria in New York City.
14y agoBIOSBioScrip to Present at Stephens Fall Investment ConferenceBusiness WireELMSFORD, N.Y.--(BUSINESS WIRE)--BioScrip, Inc. (NASDAQ: BIOS) today announced that the Company will present at the Stephens Fall Investment Conference to be held at the New York Palace Hotel in New York City on November 13-14, 2012.
14y agoBIOSBioScrip Reports Third Quarter 2012 Financial ResultsBusiness WireELMSFORD, N.Y.--(BUSINESS WIRE)--BioScrip, Inc. (NASDAQ: BIOS) today announced 2012 third quarter financial results. Third quarter revenue from continuing operations was $170.4 million and the net loss from continuing operations was $0.6 million, or $0.01 per diluted share. Consolidated Adjusted EBITDA for the third quarter was $11.6 million versus $11.7 million for the third quarter of 2011.
14y agoBIOSBioScrip to Host Third Quarter 2012 Earnings CallBusiness WireELMSFORD, N.Y.--(BUSINESS WIRE)--BioScrip (NASDAQ: BIOS) today announced that the Company will release its 2012 third quarter financial results on Wednesday, November 7, 2012, after the market closes.
14y agoBIOSBioScrip to Present at Morgan Stanley Global Healthcare ConferenceBusiness WireELMSFORD, N.Y.--(BUSINESS WIRE)--BioScrip, Inc. (NASDAQ: BIOS) today announced that the Company will present at the Morgan Stanley Global Healthcare Conference to be held at the Grand Hyatt in New York City on September 10-12, 2012.
14y agoBIOSBioScrip Reports Second Quarter 2012 Financial ResultsBusiness WireELMSFORD, N.Y.--(BUSINESS WIRE)--BioScrip, Inc. (NASDAQ: BIOS) today announced 2012 second quarter financial results. Second quarter revenue, from continuing operations, was $155.9 million and net loss, from continuing operations, was $4.3 million, or $0.07 per diluted share. Consolidated Adjusted EBITDA for the second quarter was $9.0 million.
14y agoBIOSBioScrip to Host Second Quarter 2012 Earnings CallBusiness WireELMSFORD, N.Y.--(BUSINESS WIRE)--BioScrip (NASDAQ: BIOS) today announced that the Company will release its 2012 second quarter financial results on Wednesday, August 8, 2012, after the market closes.
14y agoBIOSBioScrip to Present at Jefferies 2012 Global Healthcare ConferenceBusiness WireELMSFORD, N.Y.--(BUSINESS WIRE)--BioScrip (NASDAQ: BIOS) today announced that the Company will present at the Jefferies 2012 Global Healthcare Conference to be held at the Grand Hyatt in New York City on June 4-7, 2012.
14y agoBIOSBioScrip to Present at Bank of America Merrill Lynch 2012 Health Care ConferenceBusiness WireELMSFORD, N.Y.--(BUSINESS WIRE)--BioScrip (NASDAQ: BIOS) today announced that the Company will present at the Bank of America Merrill Lynch 2012 Health Care Conference to be held at Encore at the Wynn in Las Vegas, NV on May 15-17, 2012.
14y agoBIOSBioScrip Reports 2012 First Quarter Financial ResultsBusiness WireELMSFORD, N.Y.--(BUSINESS WIRE)--BioScrip, Inc. (Nasdaq: BIOS) today announced 2012 first quarter financial results. First quarter revenue was $155.6 million and net loss was $2.7 million, or $0.05 per share. Consolidated Adjusted EBITDA for the first quarter was $8.4 million.